Pharmaceutical
Technology
Health
Titan Pharmaceuticals
$1.829876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.82
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.04 (2.25%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell TTNP and other stocks, options, ETFs, and crypto commission-free!
About
Titan Pharmaceuticals, Inc. Common Stock, also called Titan Pharmaceuticals, is a biopharmaceutical company, which engages in developing proprietary therapeutics primarily for the treatment of medical disorders. Read More Its products include Probuphine, provides non fluctuating blood levels of buprenorphine; Ropinirole implant, which provides dopaminergic stimulation; and T3 implant, which is used in hypothyroidism treatment. Its products are subdermal implants, which utilizes ProNeura drug delivery platform. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.
Employees
13
Headquarters
South San Francisco, California
Founded
1992
Market Cap
70.07M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
748.51K
High Today
$1.88
Low Today
$1.78
Open Price
$1.78
Volume
101.76K
52 Week High
$6.90
52 Week Low
$1.03
Collections
Pharmaceutical
Technology
Health
Biopharmaceutical
Therapy
Medical
US
North America
News
PR Newswire10h
Titan Pharmaceuticals To Report Fourth Quarter And Full Year 2018 Financial Results On April 1, 2019
SOUTH SAN FRANCISCO, Calif., March 26, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that its fourth quarter and full year 2018 financial results will be released after market close on Monday, April 1, 2019. Titan will host a live conference call to discuss the financial results and provide a general business review the following day, April 2, 2019, at 8:30 a.m. ET / 5:30 a.m. PT. The call will be hosted by Sunil Bhonsle, president and CEO; Kate Beebe DeVarney, Ph.D., exec...
Seeking AlphaFeb 25
Titan Pharmaceuticals teams up with AllianceRX Walgreens Prime; shares up 65% premarket
Titan Pharmaceuticals (NASDAQ:TTNP) is up 65% premarket on executing a specialty pharmacy distribution and services agreement with AllianceRx Walgreens Prime that will expand patient access to treatment with Probuphine (buprenorphine) implant, for opioid use disorder (OUD) in eligible patients.
Price Paid on Robinhood
124% Higher
Right Now
52 Week Low
$1.03
Average Price Paid
$0.8134
52 Week High
$6.90
Earnings
-$0.20
-$0.15
-$0.09
-$0.04
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
—
Actual
—